This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TTNP Titan Pharmaceuticals (TTNP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Titan Pharmaceuticals Stock (NASDAQ:TTNP) Get Titan Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.55▼$4.8050-Day Range$3.64▼$5.9352-Week Range$3.53▼$5.76Volume3.10 million shsAverage Volume76,658 shsMarket Capitalization$7.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Titan Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary therapeutics based on its ProNeura long‐term, continuous drug delivery platform. Headquartered in South San Francisco, California, the company seeks to enhance patient outcomes through sustained‐release implants designed to deliver medication over extended periods. Titan’s platform is engineered to maintain consistent drug levels while reducing dosing frequency, with the goal of improving compliance and minimizing side effects often associated with conventional dosing schedules. The company’s lead product, Probuphine®, is a buprenorphine implant approved by the U.S. Food and Drug Administration in 2016 for maintenance treatment of opioid dependence. Probuphine delivers six months of continuous buprenorphine therapy via a small subdermal implant, offering an alternative to daily oral dosages. Titan originally commercialized Probuphine through a partnership with a specialty pharmaceutical company, and it continues to explore strategic collaborations to expand patient access within the United States and potential markets overseas. In addition to its marketed product, Titan maintains a pipeline of development programs aimed at addressing central nervous system disorders. Research efforts include next‐generation implants for migraine prophylaxis and psychiatric indications such as schizophrenia. The company’s leadership team, led by President and Chief Executive Officer Sunil Bhonsle, combines expertise in drug delivery technology and biopharmaceutical development. Titan Pharmaceuticals remains committed to advancing its ProNeura platform to bring long‐acting implant therapies to patients with chronic and complex conditions.AI Generated. May Contain Errors. Read More Receive TTNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TTNP Stock News HeadlinesTitan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan CorporationOctober 3, 2025 | globenewswire.comTitan Pharmaceuticals Approves Merger with Black TitanAugust 26, 2025 | msn.comYou’re Being LIED To About The Iran WarThe mainstream explanation for the Iran airstrikes may not be the full story. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there's a deeper motive behind the bombing campaign that most coverage is ignoring. If you're making investment decisions based on what you're hearing in the news, Wiggin argues you could be working with an incomplete picture.May 7 at 1:00 AM | Banyan Hill Publishing (Ad)TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNPAugust 5, 2025 | businesswire.comURGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)July 29, 2025 | globenewswire.comTitan Pharmaceuticals Inc (TTNP) - Investing.comJuly 4, 2025 | investing.comTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock - MorningstarJune 29, 2025 | morningstar.comMTitan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management - NasdaqJune 29, 2025 | nasdaq.comSee More Headlines TTNP Stock Analysis - Frequently Asked Questions How were Titan Pharmaceuticals' earnings last quarter? Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) released its earnings results on Thursday, August, 14th. The specialty pharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter. When did Titan Pharmaceuticals' stock split? Shares of Titan Pharmaceuticals reverse split before market open on Tuesday, January 9th 2024.The 1-20 reverse split was announced on Tuesday, January 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Titan Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Titan Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD) and Arista Networks (ANET). Company Calendar Last Earnings8/14/2025Today5/07/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TTNP CIK910267 Webwww.titanpharm.com Phone(650) 244-4990Fax650-244-4956Employees10Year Founded1992Profitability EPS (Trailing Twelve Months)($2.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.71 million Net MarginsN/A Pretax MarginN/A Return on Equity-108.60% Return on Assets-95.64% Debt Debt-to-Equity RatioN/A Current Ratio11.60 Quick Ratio11.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book2.22Miscellaneous Outstanding Shares1,330,000Free Float1,320,000Market Cap$7.88 million OptionableOptionable Beta1.37 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:TTNP) was last updated on 5/7/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredThe $1.75T "Backdoor" ticker (NOT Starlink)When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...Behind the Markets | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Titan Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
